Kura Oncology Announces Launch Of Caspian Therapeutics With $50M Financing Led By BVF Partners, With Eli Lilly Participating, To Advance Menin Inhibitor KO-7246 In Diabetes; Retains About Half Ownership
Kura Oncology split off part of its company into a new business called Caspian to focus on a diabetes medicine, keeping about half ownership and getting $50 million to fund it. This shows Kura believes in this medicine enough to create a whole new company for it, which could be a good or risky sign depending on how well the medicine works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.